EZH2 overexpression occurs in various malignancies and is associated with a poor outcome. We have so far demonstrated that EZH2 downregulates the important genes such as E-cadherin and RUNX3 by increasing histone H3K27 trimethylation. However, the mechanism of EZH2 overexpression in various cancer cells remains unclear. In this study we carried out a promoter analysis of the EZH2 gene and investigated whether a survival signal that is upregulated in cancer cells is related to overexpression at the transcription level. We also explored the clinical relevance of the signaling pathway that leads to EZH2 overexpression in breast cancer and demonstrated that MEK-ERK1/2-Elk-1 pathway leads to EZH2 overexpression. The triple-negative and ERBB2-overexpressing subtypes of breast cancer are known to contain more rapidly proliferating breast cancer cells. The signaling pathway connected to EZH2 overexpression was associated with both aggressive subtypes of breast cancer. We show the significance that overexpression of histone modifier protein EZH2 in cancer cells and our study could pave the way for EZH2 inhibition to become an efficient treatment for more aggressive breast cancers.
Introduction
Enhancer of zeste homolog 2 (EZH2) is well known to be a histone modifier protein that functions as a methytransferase at lysine 27 of histone H3 (Cao et al., 2002) . EZH2 is also a member of the polycomb group of proteins and belongs to the polycomb repressive complex 2 (PRC2) subgroup (Schuettengruber et al., 2007) , and EZH2 has an important role in X-chromosome inactivation (Plath et al., 2003) . On the other hand, there have been several reports that overexpression of EZH2 occurs in various malignancies and that it is associated with a poor outcome in prostate cancer and breast cancer (Varambally et al., 2002; Kleer et al., 2003) . In an attempt to determine the functional role of EZH2 overexpression in cancer tissue, we have already demonstrated that EZH2 downregulates important genes, such as E-cadherin and RUNX3, by increasing histone H3K27 trimethylation, which suggests that it may be an oncogene . However, the mechanism of EZH2 overexpression in various cancer cells remains unclear. Although overexpression of EZH2 protein detected by immunohistochemical staining in various clinical tissue samples is associated with a poor outcome (Bachmann et al., 2006) , the mechanism responsible for the differences in rates of cancer cell positivity between individual cases also remains unclear.
Breast cancer is a heterogeneous disease with respect to outcome and response to treatment. The clinical course and treatment of breast cancer patients are to a large extent driven by the biological characteristics of their tumors, and accurate classification of breast cancers is of major importance. Expression of estrogen receptor (ER) or progesterone receptor (PgR) and epidermal growth factor receptor 2 (ERBB2) identified by immunohistochemical staining has long guided the classification of breast cancer, and the classification has proved useful in terms of predicting outcome and guiding treatment recommendations. Hormone receptor-(ER or PgR) positive breast cancers and ERBB2-positive breast cancers currently account for 75-80% and 15-20%, respectively, of all breast cancers. About half of ERBB2-positive cancers co-express hormone receptors (Slamon et al., 1989; Konecny et al., 2003) , and the other 10-15% of breast cancers fall into the socalled triple-negative category, defined by the absence of expression of all three proteins. As a result, triplenegative breast cancers are resistant to existing targeted therapies, namely, trastuzumab and hormonal therapies. The pathways that drive proliferation of triple-negative breast cancer cells are still poorly understood. Five distinct subtypes of breast cancer, that is, a luminal subtype A, a luminal subtype B, an ERBB2-overexpressing subtype, a basal subtype and a normal breast-like subtype have been defined by RNA expression arrays (Perou et al., 2000) , and this classification has been refined by cytokeratin (CK) expression patterns. Although most basal-type breast cancers do not express ER, PgR or ERBB2 (Nielsen et al., 2004) , as a small number do, the overlap between basal-type breast cancer and triple-negative breast cancer is not complete. However, characteristically these tumors have a high mitotic count, scant stromal content, exhibit central necrosis, a pushing border of invasion, frequent apoptotic cells and a stromal lymphocytic response. The classification of breast cancers is clinically relevant because a higher proportion of patients with basal-type breast cancer have a poor outcome than patients with luminal type-breast cancer (Korsching et al., 2008) .
Previous studies have shown that increased expression of EZH2 is associated with aggressive behavior of breast cancers and a high breast cancer cell proliferation rate (Kleer et al., 2003; Bachmann et al., 2006) . In this study we carried out a promoter analysis of the EZH2 gene and investigated whether a survival signal that is upregulated in cancer cells is related to overexpression at the transcription level. We also explored the clinical relevance of the signaling pathway that leads to EZH2 overexpression in breast cancer.
Results

Promoter analysis
The À2874 to þ 599 (transcription start site designated as þ 1) long 5 0 flanking region of EZH2 was obtained by PCR amplification of human placenta genomic DNA. The fragment was then subcloned into the promoter-less luciferase reporter vector pGL3-Basic, and the putative promoter activity was measured by a dual-luciferase assay (Figure 1a ). pGL3-Basic had basal strength in the form of luc þ /Rluc activity, and that strength was set equal to 1. The deletion variants of the EZH2 promoter region yielded different basal levels of expression of the luciferase gene. One of them, pGL3-696 exhibited about twofold increase in relative luciferase activity in -2704, 2282, 2106, 1839, 1516, 1182, 1089, 696, 456 and 151 were derived from pGL3-2874. Asterisk mark focuses a difference of relative luciferase activity between pGL3-696 and pGL3-151 constructs. (c) Bioinformatic analysis of transcriptional factor binding sites in the EZH2 5 0 -flanking upstream region. Software was used to make the predictions. The numbers on the left side indicate the order upstream to the first base of the transcriptional start site. The transcription factors that bind to the region are labeled below their corresponding binding sites. The DNA sequence surrounded by two arrows was for mutation construct. (d) Three Elk-1 binding motifs were located within À453 nt and À180 nt. White and gray triangles indicate a wild or mutant sequence for Elk-1 binding motifs, respectively. WT, wild type; MT, mutant type.
comparison with that of pGL3-2874, and its activity was higher than that of the full-length promoter (pGL3-2874) (Figure 1b) . A significant difference in relative luciferase activity between pGL3-696 and pGL3-151 was exhibited as about twofold difference between the deletion variants (Po0.05), and pGL3-151 displayed much lower relative luciferase activity than pGL3-696. We focused on the region responsible for the difference in relative luciferase activity and carried out a computational analysis with the TRANSFAC 6.0 software program (BIOBASE, Beverly, MA, USA; http://www. biobase-international.com/pages/index.php?id ¼ transfac). The results revealed the expected enhancer sequences, such as CCAAT box and GC box, as well as transcription factor-binding sites. Within the À696 nt of the EZH2 5 0 flanking region, there were three Elk-1 binding motifs, as well as many general transcription factors that constitute the basal transcription apparatus and response elements, including NF-kB, c-Myb, STAT1 and SRF (serum response factor), which is known to cooperate with Elk-1 for transcriptional activation ( Figure 1c ). There were three binding sites of Elk-1 between À696 nt and -151 nt of the EZH2 5 0 flanking region (Figure 1d ), suggesting that the MEK-ERK-Elk-1 pathway, which is known to be upregulated in various cancer cells, contributes to the EZH2 overexpression. Next, we made wild and mutant constructs with one point mutation for each Elk-1 binding sites. At first, wild and mutant DNA sequences of the EZH2 promoter region encompassing the all three Elk-1 binding sites (the length is 274 bp) were synthesized, respectively, and inserted into pGL3-Basic Vector. Theafter, dual luciferase assays were carried out. The pGL3-Elk-1-MT exhibited almost a half decrease in relative luciferase activity compared with that of wild-type construct (Figure 1d ). The decreased level was similar to the difference between deletion construct without three Elk-1 binding sites (pGL3-151) and pGL3-696 construct.
Effect of inhibition of the MEK-ERK-Elk-1 pathway on EZH2 expression We proceeded to investigate whether inhibition of the MEK-ERK-Elk-1 pathway would affect EZH2 overexpression. First, the cytotoxic effect of the MEK inhibitor (U0126) on MDA-MB-231 cells was assessed by analyzing the cell growth curve. The results showed that the 40 mm concentration of the MEK inhibitor did not significantly affect cell survival, but as a higher concentration (400 mM) caused significant cell death, 40 mM was chosen as the optimal concentration to use in all experiments on MDA-MB-231 cells. The MDA-MB-231 cells were treated with 10 and 40 mM concentrations of the MEK inhibitor for 12 and 24 h, EZH2 mRNA expression started to decrease at 12, and at 24 h it had reached one-third the level in the control (Figure 2a ). Knockdown of Elk-1, the functional transcription factor present in the downstream of the MEK-ERK pathway, by small interfering RNA (siRNA) transfection caused a decrease in level of EZH2 mRNA expression that was similar to the decrease caused by MEK inhibitor treatment ( Figure 2b) . A combination of MEK inhibitor treatment and Elk-1 siRNA transfection resulted in a decrease in level of EZH2 mRNA expression that was almost the same as in response to treatment with the MEK inhibitor or Elk-1 siRNA transfection alone ( Figure 2b ). The efficiency of Elk-1 knockdown by siRNA transfection is shown in Figure 2c . We tested whether the MEK inhibitor treatment or Elk-1 knockdown by siRNA transfection affected the relative luciferase activity of EZH2 promoter. Both treatments affected the relative luciferase activity of EZH2 promoter. However, in case that pGL3-151 constructed reporter plasmids without predicted Elk-1 binding sites was transfected, the relative luciferase activity of EZH2 promoter was not affected by Elk-1 knockdown (Figure 2e ).
Phospho-Elk-1 binds to the promoter of EZH2
Computational analysis identified three Elk-1 binding sites within À696 nt of the EZH2 5 0 -flanking region ( Figure 1c) . We designed the three sets of PCR primers for the chromatin immunoprecipitation (ChIP) assay so that the amplified region would include or would not include Elk-1 binding sites (Figure 3a) . We carried out the ChIP assay to determine whether phospho-Elk-1 or generic Elk-1 binds to a region of EZH2 gene ( Figure 3a and ChIP primer for GAPDH gene promoter. ChIP assay was performed by using DNA-protein complex isolated from MDA-MB-231 cells treated with the MEK inhibitor for 24 h or transfected with Elk-1 siRNA for 48 h, and immunoprecipitated with phospho-Elk-1 (pElk-1) or generic Elk-1 (Elk-1) antibody. The ratio of immunoprecipitated DNA to input DNA was quantified by performing a DNA 1000 assay with the Agilent 2100 bioanalyzer. Individual ChIP assays were carried out a total of at least three times to confirm the reproducibility of the PCR-based experiment. the control after Elk-1 siRNA transfection (Po0.05) (Figures 3b and c) . The binding level of Elk-1 to the EZH2 promoter that was detected using a generic antiElk-1 antibody also decreased after MEK inhibitor treatment or Elk-1 knockdown (Figures 3b and c) , which suggests that the generic anti-Elk-1 antibody used here recognizes phosphorylated Elk-1, as well as nonphosphorylated Elk-1. On the other hand, it was so difficult to detect signal intensity reflecting binding levels of phospho-Elk-1 to the EZH2 promoter region without any predicted Elk-1 binding motif and to the nontargeted gene such as GAPDH by PCR-based method (Figure 3d ). These results suggest that the level of phospho-Elk-1 binding to the EZH2 promoter region with the predicted Elk-1 binding sites regulates the transcription of EZH2 mRNA.
MEK-ERK-Elk-1 pathway regulates EZH2 protein expression in triple-negative and ERBB2-overexpressing breast cancer cell lines
The findings described thus far demonstrated the existence of MEK-ERK-Elk-1 pathway that functions as a regulator of EZH2 mRNA overexpression in triplenegative breast cancer MDA-MB-231. In the next step, we investigated whether the pathway has a role in regulating EZH2 protein expression in the three different types of breast cancer cell lines, that is, the triple-negative/basal-type (MDA-MB-231 and MDA-MB-468), ERBB2 overexpressing/luminal B type (SKBr3), and hormone receptor-positive type (HCC1500). As shown in Figure 4a , the western blot analysis showed that MEK inhibitor (U0126) treatment decreased EZH2 protein expression in MDA-MB-231 cells. The decrease of EZH2 protein started 4 h after U0126 treatment and it was accompanied by a disappearance of phosphorylation of Elk-1. The decrease of EZH2 protein after U0126 treatment for 12 h was accompanied by a decrease in phosphorylation of both ERK1/2 and Elk-1 (Figure 4b ). Knockdown of Elk-1 by siRNA transfection also decreased EZH2 protein expression and decreased Elk-1 of phosphorylation, without decreasing the phosphorylation level of pERK1/2, because Elk-1 is a downstream protein of the MEK-ERK1/2 pathway ( Figure 4c ). These results were the same as obtained in regard to EZH2 mRNA after MEK inhibitor treatment and Elk-1 siRNA transfection (Figure 2 ). MEK inhibitor treatment for 12 or 24 h decreased EZH2 protein expression in MDA-MB-468 cells and SKBr3 cells, and the decrease was also accompanied by a decrease in phosphorylation of both ERK1/2 and Elk-1 (Figures 4d and e) , results that were similar to those observed in MDA-MB-231 cells. On the other hand, U0126 treatment or Elk-1 knockdown by siRNA transfection did not have any effect on EZH2 expression in HCC1500 cells (Figure 4f ). Next, we treated MDA-MB-231 cells with Akt inhibitor or PI3K inhibitor to determine the specificity of MEK inhibitor with respect to EZH2 expression. AKT inhibitor did not affect EZH2 expression, phospho-AKT was not detected in MDA-MB-231 cells by western blot analysis (Figure 4g ), which was same as previous published data ( Kenny et al., 2007) . EZH2 mRNA expression also did not change after treatment with Akt inhibitor (Supplementary Figure 1 ). PI3K inhibitor (LY294002) did affect negatively EZH2 expression. PI3K inhibitor decreased the phosphorylation level of ERK1/2 and Elk-1 (Figure 4g ), however, the decrease was not remarkable. The result of real-time reverse-transcription PCR (RT-PCR) showed that PI3K inhibitor decreased EZH2 mRNA expression level (Figure 4h ). These results suggest that PI3K inhibitor affect EZH2 expression negatively by downregulating MEK-ERK-Elk-1 pathway. The previous report shows that Rac exerts an effect downstream of PI3K to have enhancing role in regulation of the Raf/Erk signaling pathway downstream of Ras activated. PI3k inhibitor, LY294402 inhibited Erk activation by inhibiting Rac activation (Arai et al., 2002) . However, another downstream effector of PI3K may have a role in activation of Erk/ Elk-1, further studies on signaling downstream of PI3K for regulation of EZH2 expression will be required to elucidate the molecular mechanisms.
EZH2 overexpression induced by the activated MEK-ERK1/2 pathway occurs in ERBB2-overexpressing and triple-negative breast cancer subtypes
We also explored the relevance of the signaling pathway that leads to EZH2 overexpression in breast cancer tissue. The result of immunohistochemical staining of the representative case with triple-negative breast cancer was shown in Figure 5 . The cancer cells showed positivity for EGFR and pElk-1. The EZH2 that is supposed to be a downstream protein of MEK/ERK/ Elk-1 pathway from the findings thus far demonstrated was overexpressed, and high MIB-1 index was also observed in the same area (Figures 5b-e) . The two continuous and thin tissue sections showed the synchronized co-overexpression of EZH2 and pElk-1 proteins in individual cancer cells (Figures 5b and c) . Among 178 breast cancer tissues, there was a significant correlation between EZH2 overexpression and breast cancer phenotype, the EZH2 protein expression positive rates of the ERBB2-overexpressing and triple-negative subtypes were much higher than that of the hormone receptorpositive subtype (Figure 6a ). The percentages of cases classified as EZH2-overexpressing cases in the ERBB2-overexpressing subtype and triple-negative breast cancer subtype were much higher than in the hormone receptor-positive subtype (Figure 6b ), suggesting that the MEK-ERK pathway mainly causes EZH2 overexpression in ERBB2-overexpressing and triple-negative breast cancer cells. In addition, the percentages of cases classified as RUNX3-negative or RUNX3-weakly expressed in cytoplasm in the triple-negative breast cancer subtype were much lower than in the hormone receptorpositive subtype (Figure 6c ). We treated MDA-MB-231 cells with Elk-1 siRNA transfection and examined whether the expression of RUNX3 mRNA changed. As shown in Figure 6d , the expression of RUNX3 mRNA started to increase 72 h after Elk-1 knockdown. This result is similar to our previous result that RUNX3 expression is restored 72-96 h after knockdown of EZH2 . We would like to propose the signaling pathway leading to EZH2 overexpression in breast cancer cells (Figure 6e ).
Discussion
The results of this study showed that the MEK-ERKElk-1 pathway, which is one of the signal transduction pathways that are upregulated in cancer cells, is linked to overexpression of EZH2, which is one of the histone modifier proteins. EZH2 has been reported to be overexpressed in various cancer cells (Raaphorst et al., 2000; Varambally et al., 2002; Kleer et al., 2003; Bachmann et al., 2006; , suggesting that the overexpression is caused by a variety of signals and pathways, some of which are specific to certain kinds of cancer cell and others of which are universal. The results provided evidence that Elk-1 is a critical factor downstream from ERK not only as a transcription factor for several other genes, but also for EZH2, resulting in chromatin remodeling at certain specific foci, such as RUNX3 and E-cadherin . We concluded that ERK has a pleiotropic role in gene regulation by controlling the phosphorylation of transcription factors, including Elk-1, and chromatin remodeling via EZH2 and histone H3 methylation. These effects seemed to be critical to the aggressiveness and high growth rate of triple-negative breast cancer (Figure 6 ). However, other transcriptional factors may bind to certain binding motifs in the EZH2 promoter, and further experiments are needed to identify the factors that regulate EZH2 expression and are associated with the character of cancer cells, specifically with cancer cell phenotypes. The mechanism proposed here may be just one of several different mechanisms that impact EZH2 levels and function in cancer cells. There is precedent for microRNA regulation that affects both EZH2 mRNA and protein levels (Varambally et al., 2008) and also non-coding RNA that can control EZH2 targeting in cancer cells (Gupta et al., 2010) . The comprehensive understanding of these multiple modes of controlling EZH2 expression is necessary and further studies are needed to clarify the connection of these modes related to cancer aggressive phenotypes such as invasiveness and metastasis. The full-length reporter plasmid constructed did not exhibit the peak relative luciferase activity. A positive transcriptional effect of phospho-Elk-1 binding on the 
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promoter was shown in this study, but the longer deletion variants of the constructed reporter plasmid exhibited relative low luciferase activity, suggesting that there may be binding sites for repressive transcriptional factors in those regions of the EZH2 promoter. The plausible possibility that EZH2 transcription is regulated by a variety of transcriptional factors would suggest that histone modification by a histone modifier protein such as EZH2 may be reversible in response to several factors in the microenvironment, including inflammation, hypoxia and carcinogen exposure around normal or cancer cells. Histone modifier proteins are capable of the transcription of a whole set of genes simultaneously. Further study will be needed to devise a methodology for cancer treatment by regulating the expression of histone modifier proteins. Western blot analyses of ERBB2-positive and triplenegative breast cancer cell lines were carried out to explore the extent of the inhibitory effect of MEK inhibitor treatment or Elk-1 knockdown on EZH2 protein expression (Figure 4) . The remarkable effect of the MEK inhibitor on EZH2 protein in triple-negative and ERBB2-overexpressing cells suggests that the MEK/ERK pathway activated via KRAS mutation, EGFR amplification and ERBB2 amplification contribute strongly to EZH2 overexpression. In fact, MDA-MB-231 and MDA-MB-468 cells are KRAS mutant and EGFR amplified breast cancer cells, respectively (Hollestelle et al., 2010) . Tissue microarray studies have shown a high rate of EGFR overexpression in triplenegative breast cancers (Cleator et al., 2007) . In this study, the EZH2 protein expression positive rates of the ERBB2-overexpressing and triple-negative subtypes were much higher than that of the hormone receptorpositive subtype (Figure 6a ). On the basis of the results of this study, we think that EZH2 inhibition is a critical treatment in triple-negative and ERBB2-overexpressing breast cancer cells.
Many phenotypical and molecular features, including ER negativity, high nuclear grade, high Ki-67 staining, CK5/6 expression, EGFR expression and p53 mutation, are shared by sporadic triple-negative breast cancers and tumors that arise in carriers of the BRCA1 mutation (Crook et al., 1998; Srlie et al., 2001; Foulkes et al., 2004) . BRCA1 is rarely mutated in sporadic breast cancers (Futreal et al., 1994) , however, the histopathological similarity of the two categories; triple-negative breast cancers and tumors with the BRCA1 mutation leads us to speculate that common pathways may be associated with cancer cell proliferation. Interestingly, a recent study immunohistochemically demonstrated a clear increase in EZH2 protein levels in tumors from BRCA1 mutation carriers (Puppe et al., 2009) . It also showed that BRCA1-deficient cancer cells are selectively dependent on their elevated EZH2 levels and that inhibition of EZH2 is about 20-fold more effective in killing BRCA1-deficient cells than in killing BRCA1-proficient mammary tumor cells, suggesting that EZH2 may be a target for drug therapy of a specific subtype of breast cancer. The results of our present study suggest that inhibition of EZH2 may critically block cancer cell proliferation in aggressive breast cancer phenotypes, including triple-negative breast cancers and BRCA1-deficient breast cancers.
The findings in this study showed that EZH2 overexpression was caused by activated MEK-ERK1/ 2-Elk-1 pathway. The signaling pathway connected to EZH2 overexpression is associated with aggressive phenotypes of breast cancer including triple-negative and ERBB2-overexpressing breast cancers. Our study could pave the way for EZH2 inhibition to become an efficient treatment for more aggressive breast cancers.
Materials and methods
Bioinformatic analysis and cloning of the EZH2 gene promoter region By using the 5 0 complementary DNA sequence of the EZH2 gene as a probe, exons of the EZH2 gene were identified as corresponding to the sequences of the nucleotides on human chromosome 7 (Gene Accession Number NC_000007. 12) by a BLAST search. The promoter and transcription binding sites on the 5 0 flanking region of EZH2 were predicted by conducting a TRANSFAC 6.0 analysis. The full-length EZH2 gene promoter region from the 5 0 flanking 2874-bp upstream region to 599-bp downstream region from the transcription starting site of the EZH2 gene (148135408-148212347) was amplified by using human genomic placenta DNA (50 ng/ml) as a template and a PCR primer with an incorporated MluI site (EZH2À2874), and a primer with an incorporated BglII site (EZH2 þ 599R) (Supplementary Table 1 ). The PCR product after digestion with BglII and MluI was inserted into the pGL3-Basic vector (Promega, Madison, WI, USA), and the entire length of the inserted PCR product was sequenced by using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA) and the designed sequence primers (Supplementary Table 1 ).
Construction of recombinant luciferase reporter plasmids with the full-length EZH2 gene promoter region, deletion variants and mutation variant The whole BglII-MluI fragment of the recombinant plasmid was subcloned into the BglII-MluI site of the MCS of the pGL3-Basic vector (Promega), and the plasmid obtained was designated as pGL3-2874. Several deletion variants designated as pGL3-2704 , pGL3-2282 , pGL3-2106 , pGL3-1839 , pGL3-1516 , pGL3-1182 , pGL3-1089 were generated using primer sets of the forward primer with an incorporated MluI site or the reverse primer with an incorporated BglII site (Supplementary Table 1) as described above. The wild and mutant DNA sequences of the EZH2 promoter region encompassing all the three Elk-1 binding sites (À453 nt to À180 nt) were synthesized, respectively and inserted into pGL3-Basic Vector. The wild-type and mutant-type constructs were designated as the pGL3-Elk-1-WT and pGL3-Elk-1-MT, respectively. T was replaced into A in each Elk-1 binding motif of pGL3-Elk-1-MT construct.
Cell culture and transfection of reporter plasmids Human breast cancer cell line MDA-MB-231 was routinely grown in RPMI medium containing 10% fetal bovine serum and 10% glutamine. The reporter plasmids were transfected with Lipofectamine 2000 (Invitrogen, Camarillo, CA, USA).
Dual-luciferase reporter assay
Dual-luciferase reporter assays with the constructed reporter plasmids were carried out according to the manufacturer's instructions (Promega). pRL-SV40 plasmid (Promega) was co-transfected to normalize the transfection efficiency. Transfections were carried out on 12-well plates, and the reporter assays were carried out on 96-well plates. Briefly, 4 h after transfection, the cell culture medium was replaced with fresh complete growth medium, and the cells were incubated for another 20 h. The activity of firefly (Photinus pyralis) and Renilla (Renilla reniformi) luciferases (luc þ and Rluc, respectively) in cell lysates was measured sequentially with a 96-well plate luminometer (Luminescencer-JNR AB-2100, Atto Bio-Instrument, Tokyo, Japan). Promoter strength was expressed as luc þ activity/Rluc activity.
Breast cancer cell lines
Three breast cancer cell lines, that is, MDA-MB-231, MDA-MB-468, SKBr3, and HCC1500, all obtained from the American Type Culture Collection (Manassas, VA, USA), were maintained at 37 1C in RPMI supplemented with 10% heat-inactivated fetal bovine serum and 1% glutamine under a 5% CO 2 atmosphere. MDA-MB-231 and MDA-MB-468 are basal-type breast cancer cell lines, which are defined by triple negativity for ER, PgR and ERBB2. SKBr3 cells are characterized by ERBB2 expression, HCC1500 cells are characterized by hormone-receptor expression (Hollestelle et al., 2010) .
RNA isolation and real-time RT-PCR
Total RNA from the cell lines was isolated with TRIzol Reagent (Invitrogen) and reverse transcribed to complementary DNA with ExScript RT Reagent (Takara, Yokkaichi, Mie, Japan). Real-time RT-PCR was carried out with specific primers for EZH2 and Elk-1 and a Smart Cycler (Cepheid, Sunnyvale, CA, USA). GAPDH expression was used to normalize for variance. Real-time fluorescence monitoring of the PCR products was performed with SYBR Green I fluorescent dye (Takara). The levels of expression of specific genes are reported as ratios to the level of expression of GAPDH in the same master reaction. The PCR primer pairs (5 0 to 3 0 ) used for each gene were: EZH2, CCCTGACCTCTG TCTTACTTGTGGA and ACGTCAGATGGTGCCAGCA ATA; Elk-1, CACTTCTGGAGCACCCTGAGTC and AGA GGCCATCCACGCTGATA; and GAPDH, GCACCGTCA AGGCTGAGAAC and ATGGTGGTGAAGACGCCAGT. These primer sets were designed by Takara.
MEK inhibitor, PI3K inhibitor and Akt inhibitor treatment MDA-MB-231 cells were treated with a MEK inhibitor (U0126) (Promega) at a concentration of 40 mM for 4, 8, 12 and 24 h, and the other cell lines, including MDA-MB-468 and SKBr3 cells, were treated with the MEK inhibitor at 50 mM. MDA-MB-231 cells were treated with a PI3K inhibitor (LY294002) (Calbiochem, Darmstadt, Germany) or an Akt inhibitor (Akt inhibitor V, Triciribine) (Calbiochem) at a concentration of 1, 5, 10, 25, 50 mM for 24 h. Total RNA from the treated cell lines was then isolated and used for real-time RT-PCR for EZH2, Elk-1 and GAPDH, ChIP assay and western blot analysis.
RNA interference
Two 21-nucleotide duplex siRNA for Elk-1 and one negative control siRNA were synthesized by Ambion (Carlsbad, CA, USA), Inc. (Elk-1 siRNA ID, s4634; Elk-1 siRNA-1 and s4633; Elk-1 siRNA-2), and 24 h after plating the cells they were transfected with Elk-1 siRNA or control siRNA by using the DharmaFECT transfection reagent (Dharmacon, Lafayette, CO, USA) according to the manufacturer's instructions. Cells were harvested 48 h after transfection and subjected to several assays, including real-time RT-PCR, ChIP assay and western blot analysis.
Chromatin immunoprecipitation assay
The ChIP assay was carried out as previously described (Fujii et al., 2003) . The PCR conditions for the EZH2 gene (Gene Accession Number NC_000007.12) promoter, which contains or does not contain Elk-1 biding motifs, were applied with the following three primer pairs: ChIP primer 1 which contains three Elk-1 binding motifs (5 0 to 3 0 ): TTAAAACCGTTACCA CCCCCGAGTTTTGAA and TTCGCTGTAAGGGACGCC ACTGGCCGTGT, ChIP primer 2 which contains two Elk-1 binding motifs (5 0 to 3 0 ): AACTCTGCGGCGCCGGTT CCCGCCAAGA and TTCGCTGTAAGGGACGCCACTG GCCGTGT and ChIP primer 3 which does not contain any Elk-1 binding motifs (5 0 to 3 0 ): ACGAACAGTGGA AGGGTCTG and GGAGTTTCGCTCTGGTTGTC. A ChIP primer pair for GAPDH as negative control for Elk-1 binding was used (5 0 to 3 0 ): CACCGTGTGCCCAAGACCTC and CAGCCCTGTAGCCTGGACCT (Morris et al., 2005) . A 5mg amount of antibody was used in this assay. The antibodies used were phospho-Elk-1 and generic (pan-reactive) Elk-1 antibody purchased from Spring Bioscience (Pleasanton, CA, USA). Individual ChIP assays after treatment with the MEK inhibitor and Elk-1 siRNA transfection were carried out at least three times to confirm the reproducibility of the PCRbased experiment. Preliminary PCR reactions were carried out to determine the optimal PCR conditions to assure linear amplification of the DNA. To measure the level of phosphoElk-1 or generic Elk-1 binding in each immunoprecipitate, the ratios of immunoprecipitated DNA to input DNA were calculated by measuring the intensity of the PCR product in immunoprecipitated DNA versus input DNA (total chromatin) amplified by PCR in a linear range. The ratios were calculated using the PCR products by performing a DNA 1000 assay with the Agilent 2100 bioanalyzer and using DNA chips for electrophoresis (Agilent Technologies, Santa Clara, CA, USA).
Western blot analysis
Cells were lysed with whole-cell lysis buffer (80 mM glycerophosphate, 20 mM EGTA, 15 mM MgCl 2 , 20 mM NAF, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 10 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride and a protease inhibitor tablet (Roche, Mannheim, Germany), and the lysates were frozen in liquid nitrogen and thawed three times to rupture the cell membranes. Samples of the lysates were incubated for 30 min on ice to lyse the nuclei and then centrifuged at 8900 rpm. The protein concentration of each sample was determined with a BCA Protein Asssay Kit (Pierce, Rockford, IL, USA). Equal amounts of protein (20 mg) from each cell line were subjected to western blot analysis. The probing antibodies were EZH2 antibody (1:1000) (BD Transduction Laboratories, Sparks, MD, USA), phospho-p44/42 MAPK (ERK1/2) antibody (1:1000) (Cell Signaling Technology, Boston, MA, USA), p44/42 MAPK (ERK1/2) antibody (1:1000) (Cell Signaling Technology), phospho-Elk-1 antibody (1:200) (Santa Cruz, Santa Cruz, CA, USA), Elk-1 antibody (1:200) (Santa Cruz), Akt antibody (1:1000) (Cell Signaling Technology), pAkt antibody (Ser 473) (Cell Signaling Technology), and b-actin antibody (1:50) (Santa Cruz).
Breast cancer tissue samples A total of 178 breast cancer specimens that had been histologically diagnosed as invasive ductal carcinoma were studied and classified into three types: a hormone receptorpositive type (ER-and/or PgR-positive), an ERBB2-overexpressing type (ERBB2-overexpressing with/without hormone-receptor-positive) and triple-negative type (hormone receptor-negative and ERBB2 not overexpressed). All specimens were obtained from females (mean age 58.3 years; s.d.±11.1) by surgical resection at the National Cancer Hospital East, and the histological diagnosis was carried out by routine microscopic analysis of sections of formalin-fixed, paraffin-embedded specimens. None of the patients had received any preoperative treatment, including radiation therapy, hormone therapy or chemotherapy. A representative section that included the maximum diameter of the tumor was used for the immunohistochemical analysis. All clinicopathological data were according to the TNM classification (UICC) and obtained from the clinical and pathology records. Several clinicopathological factors were shown in Supplementary Table 2.
Immunohistochemical staining
The breast cancer tissues were used for the immunohistochemical analysis. Immunohistochemistry for EZH2 (1:25) (BD Transduction Laboratories), phospho-Elk-1 (1:25) (Spring Bioscience), MIB-1 (1:50) (Dako, Tokyo, Japan), EGFR (1:50) (Novocastra, New Castle, UK) and RUNX3 (1 mg/ml) (R3-6E9) (Ito et al., 2005) was carried out on sections of formalin-fixed, paraffin-embedded tissue by microwaveinduced epitope retrieval and with the Dako Envision detection system. Appropriate positive and negative internal controls were used to validate immunohistochemical staining.
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